Question · Q3 2025
Yuri inquired about the gross-to-net favorability for Vivitrol and Aristada due to Medicaid utilization, whether more such benefits are expected, and the current inventory levels for these products.
Answer
Todd Nichols, Chief Commercial Officer, stated that no additional gross-to-net favorability from Medicaid is assumed, noting that the benefit was related to the percentage of Medicaid in the channel mix, not absolute volume. He also mentioned expecting a smoother inventory pattern from Q4 2025 into Q1 2026.